Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
For people with blood/bone marrow conditions (MDS group):
- People of any age and either sex are eligible to be considered.
- People who have been diagnosed with, or are suspected of having, certain bone marrow or blood conditions, including MDS (myelodysplastic syndromes), related overlap conditions, chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (aCML), a secondary form of acute myeloid leukemia that developed from MDS, or earlier-stage conditions that may carry a risk of developing into MDS (confirm with trial site for the full list).
- People who have received any amount of prior treatment, or who are currently receiving treatment for their condition at the time of joining.
- People who have an identified specialist doctor or general doctor outside of the study hospital who has agreed to manage their ongoing care and review any findings from this study.
For bone marrow donor participants (control group):
- People of either sex who meet the bone marrow donation requirements set by the NIH Clinical Center.
- People who have no personal history of the blood or bone marrow conditions listed above, and who do not currently have an autoimmune disease.
- People who are already scheduled for a bone marrow donation procedure for medical use, or who are scheduled for a clinical bone marrow sample as part of an investigation into a possible cancer diagnosis.
For all participants:
- People who are willing to follow all study procedures and are available for the full duration of the study.
- People, or their parent or guardian, who are able to understand and willing to sign a written consent form.
Who may not be able to join:
- People with an ongoing illness (physical or psychiatric) that is not under control and that could interfere with their ability to participate in the study, or where the study doctor determines participation would not be appropriate.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Kathy L McGraw, Ph.D., National Cancer Institute (NCI)
Phone: (240) 858-7666
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
characterize the natural history of myelodysplastic syndromes (MDS) and to assess overall and progression free survival
Can't join this trial?
Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.